EUROPEAN COMMISSION ISSUES MARKETING AUTHORIZATION FOR PREOTACT

A A

NPS Pharmaceuticals, Inc. and its partner Nycomed announced today that the European Commission has granted marketing authorization for Preotact (parathyroid hormone [rDNA origin] for injection). Preotact is the European brand name for PREOS which

NPS licensed to Nycomed in 2004 for development and marketing in Europe.

CNW Group (http://www.newswire.ca/en/releases/archive/April2006/26/c0830.html)